Amarin Corporation PLC (NASDAQ: AMRN) has recently received a number of price target changes and ratings updates:

  • 8/7/2017 – Amarin Corporation PLC was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies. “
  • 8/5/2017 – Amarin Corporation PLC was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 8/3/2017 – Amarin Corporation PLC had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
  • 8/3/2017 – Amarin Corporation PLC had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $7.00 price target on the stock.
  • 7/28/2017 – Amarin Corporation PLC was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 7/11/2017 – Amarin Corporation PLC was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $4.75 price target on the stock. According to Zacks, “Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies. “
  • 7/6/2017 – Amarin Corporation PLC was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 7/3/2017 – Amarin Corporation PLC was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies. “
  • 6/30/2017 – Amarin Corporation PLC was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 6/30/2017 – Amarin Corporation PLC had its price target raised by analysts at Jefferies Group LLC from $5.00 to $7.00. They now have a “buy” rating on the stock.
  • 6/29/2017 – Amarin Corporation PLC is now covered by analysts at Jefferies Group LLC. They set a “reduce” rating and a $3.50 price target on the stock.
  • 6/28/2017 – Amarin Corporation PLC had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
  • 6/26/2017 – Amarin Corporation PLC had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $10.00 price target on the stock. They wrote, “When it comes to REDUCE-IT, less is more. We expect positive results from the REDUCE-IT outcomes study in ~mid-2018. There will be an interim analysis on ~80% of targeted cardiovascular (CV) events expected as early as ~3Q17. If REDUCE-IT is successful, Amarin will expand its sales force from ~135 reps to 400-500 in the U.S. We also think Amarin will increase its promotion to consumers. There are two things that give us confidence that the data will be positive: 1) The JELIS study tested the effects of long-term use of EPA in addition to a statin in patients with hypercholesterolemia and showed a 19% risk reduction in CV events, and 2) There are over 40 papers which support the correlation between TGs and CV risk. According to physicians, an 8%-10% risk reduction would be considered a success for REDUCE-IT.””
  • 6/12/2017 – Amarin Corporation PLC was given a new $5.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 6/12/2017 – Amarin Corporation PLC had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $5.00 price target on the stock.

Shares of Amarin Corporation PLC (NASDAQ AMRN) opened at 3.64 on Tuesday. The stock’s market cap is $985.71 million. Amarin Corporation PLC has a one year low of $2.56 and a one year high of $4.47. The company has a 50 day moving average price of $3.77 and a 200-day moving average price of $3.29.

Amarin Corporation PLC (NASDAQ:AMRN) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.01. The company had revenue of $44.95 million for the quarter, compared to analysts’ expectations of $40.35 million. The business’s revenue for the quarter was up 37.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.07) EPS. Equities analysts predict that Amarin Corporation PLC will post ($0.22) earnings per share for the current fiscal year.

In related news, General Counsel Joseph T. Kennedy sold 307,911 shares of the stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $4.00, for a total transaction of $1,231,644.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 3.72% of the company’s stock.

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Receive News & Ratings for Amarin Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.